MicroRNA-17-5p inhibits thyroid cancer progression by suppressing Early growth response 2 (EGR2)

References

• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132.
   PubMed Web of Science ®Google Scholar
• Ruan X, Shi X, Dong Q, et al. Antitumor effects of anlotinib in thyroid cancer. Endocr Relat Cancer. 2019;26(1):153–164.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang H, Wang H, et al. Long non-coding RNA DUXAP8 promotes the cell proliferation, migration, and invasion of papillary thyroid carcinoma via miR-223-3p mediated regulation of CXCR4. Bioengineered. 2021;12(1):496–506.
   PubMed Web of Science ®Google Scholar
• McFarland DC, Misiukiewicz KJ. Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer. Onco Targets Ther. 2014;7:1291–1299.
   PubMed Web of Science ®Google Scholar
• Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer. 2009;16(1):17–44.
   PubMed Web of Science ®Google Scholar
• Pemayun TG. Current diagnosis and management of thyroid nodules. Acta Med Indones. 2016;48(3):247–257.
   PubMed Web of Science ®Google Scholar
• Tuttle RM. Controversial issues in thyroid cancer management. J Nucl Med. 2018;59(8):1187–1194.
   PubMed Web of Science ®Google Scholar
• Sun Z, Shi K, Yang S, et al. Effect of exosomal miRNA on cancer biology and clinical applications. Mol Cancer. 2018;17(1):147.
   PubMed Web of Science ®Google Scholar
• Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015;15(6):321–333.
   PubMed Web of Science ®Google Scholar
• Gambari R, Brognara E, Spandidos DA, et al. Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology (Review). Int J Oncol. 2016;49(1):5–32.
   PubMed Web of Science ®Google Scholar
• Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol. 2014;9:287–314.
   PubMed Web of Science ®Google Scholar
• Bi CL, Zhang YQ, Li B, et al. MicroRNA‐520a‐3p suppresses epithelial‐mesenchymal transition, invasion, and migration of papillary thyroid carcinoma cells via the JAK1‐mediated JAK/STAT signaling pathway. J Cell Physiol. 2018;4:4054‐4067.
   Google Scholar
• Wang X, Qi M. miR‐718 is involved in malignancy of papillary thyroid cancer through repression of PDPK1. Pathol Res Pract. 2018;214:1787‐1793.
   Web of Science ®Google Scholar
• Luo LI, Xia LI, Zha B, et al. miR‐335‐5p targeting ICAM‐1 inhibits invasion and metastasis of thyroid cancer cells. Biomed Pharmacother. 2018;106:983‐990.
   Web of Science ®Google Scholar
• Song J, Liu Y, Wang T, et al. MiR-17-5p promotes cellular proliferation and invasiveness by targeting RUNX3 in gastric cancer. Biomed Pharmacother. 2020;128:110246.
   PubMed Web of Science ®Google Scholar
• Xu J, Meng Q, Li X, et al. Long noncoding RNA MIR17HG promotes colorectal cancer progression via miR-17-5p. Cancer Res. 2019;79(19):4882–4895.
   PubMed Web of Science ®Google Scholar
• Cai N, Hu L, Xie Y, et al. MiR-17-5p promotes cervical cancer cell proliferation and metastasis by targeting transforming growth factor-β receptor 2. Eur Rev Med Pharmacol Sci. 2018;22(7):1899–1906.
   PubMed Web of Science ®Google Scholar
• Zhao J, Xiao A, Liu C, et al. The HIF-1A/miR-17-5p/PDCD4 axis contributes to the tumor growth and metastasis of gastric cancer. Signal Transduct Target Ther. 2020;5(1):46.
   PubMed Web of Science ®Google Scholar
• Takakura S, Mitsutake N, Nakashima M, et al. Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Sci. 2008;99(6):1147–1154.
   PubMed Web of Science ®Google Scholar
• Shi YP, Liu GL, Li S, et al. miR-17-5p knockdown inhibits proliferation, autophagy and promotes apoptosis in thyroid cancer via targeting PTEN. Neoplasma. 2020 Mar;67(2):249–258.
   PubMed Web of Science ®Google Scholar
• Topilko P, Schneider-Maunoury S, Levi G, et al. Krox-20 controls myelination in the peripheral nervous system. Nature. 1994;371:796–799.
   PubMed Web of Science ®Google Scholar
• Zang CS, Huang HT, Qiu J, et al. MiR-224-5p targets EGR2 to promote the development of papillary thyroid carcinoma. Eur Rev Med Pharmacol Sci. 2020;24(9):4890–4900.
   PubMed Web of Science ®Google Scholar
• Unoki M, Nakamura Y. EGR2 induces apoptosis in various cancer cell lines by direct transactivation of BNIP3L and BAK. Oncogene. 2003;22:2172–2185.
   PubMed Web of Science ®Google Scholar
• Wei L, Ran F. MicroRNA-20a promotes proliferation and invasion by directly targeting early growth response 2 in non-small cell lung carcinoma. Oncol Lett. 2018;15(1):271–277.
   PubMed Web of Science ®Google Scholar
• Qiu W, Yang Z, Fan Y, et al. MicroRNA-613 inhibits cell growth, migration and invasion of papillary thyroid carcinoma by regulating SphK2. Oncotarget. 2016;7(26):39907–39915.
   PubMedGoogle Scholar
• Guo F, Fu Q, Wang Y, et al. Long non-coding RNA NR2F1-AS1 promoted proliferation and migration yet suppressed apoptosis of thyroid cancer cells through regulating miRNA-338-3p/CCND1 axis. J Cell Mol Med. 2019;23(9):5907–5919.
   PubMed Web of Science ®Google Scholar
• Sui GQ, Fei D, Guo F, et al. MicroRNA-338-3p inhibits thyroid cancer progression through targeting AKT3. Am J Cancer Res. 2017;7(5):1177–1187.
   PubMed Web of Science ®Google Scholar
• Liu L, Yang J, Zhu X, et al. Long noncoding RNA H19 competitively binds miR-17-5p to regulate YES1 expression in thyroid cancer. FEBS J. 2016;283(12):2326–2339.
   PubMed Web of Science ®Google Scholar
• Dzialo-Hatton R, Milbrandt J, Hockett RD Jr, et al. Differential expression of Fas ligand in Th1 and Th2 cells is regulated by early growth response gene and NF-AT family members. J Immunol. 2001;166(7):4534–4542.
   PubMed Web of Science ®Google Scholar
• Unoki M, Nakamura Y. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene. 2001;20(33):4457–4465.
   PubMed Web of Science ®Google Scholar
• Chen P, Zhao H, Huang J, et al. MicroRNA-17-5p promotes gastric cancer proliferation, migration and invasion by directly targeting early growth response 2. Am J Cancer Res. 2016;6(9):2010–2020.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang Y, Liu L, et al. NFAT2 overexpression suppresses the malignancy of hepatocellular carcinoma through inducing Egr2 expression. BMC Cancer. 2020;20(1):966.
   PubMed Web of Science ®Google Scholar